The American Association for Clinical Chemistry (AACC) is offering this critical and timely audioconference, providing vital information on how the new, evidence-based chronic kidney disease testing guidelines will affect laboratories and patients.
According to the National Kidney Foundation (NKF) forty million Americans are estimated to either have undiagnosed chronic kidney disease or are at increased risk for the disease. Recently, the NKF released 15 new clinical practice guidelines for chronic kidney disease designed to standardize the definition and staging of the disease.
Register and know:
* The motivation behind the guideline change* The new definition of chronic kidney disease* The stages and prevalence of chronic kidney disease* How a person's risk of developing chronic kidney disease is assessed* The recommended lab testing for detecting chronic kidney disease stages* Which laboratory tests are not recommended* The recommended "clinical action plans" for each stage* Why glomerular filtration rate (GFR) is considered the best measure of chronic kidney disease* How the new chronic kidney disease guidelines will drive therapeutic intervention
Don't miss this educational event to fully understand the NEW chronic kidney disease testing guidelines and their effects on the laboratory and patient management. Registration is by site and entitles you to the conference materials and one telephone connection for as many attendees as you want to invite.
RSS